In connection with making IntraBio Inc. a wholly owned subsidiary, Shionogi & Co., Ltd. borrowed a 3,000 hundred million yen bridge loan from Sumitomo Mitsui Banking Corporation. The agreement date and execution date are both 2026-11-10. The final repayment date is 2027-10-29. The loan is planned to be refinanced into medium- to long-term funding before the repayment date. The impact on consolidated results for the fiscal year ending March 2027 is estimated to be minimal.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4507","jir_company_name":"Shionogi & Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-11-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4507-20261110-01.pdf","jir_short_summary":"In connection with making IntraBio Inc. a wholly owned subsidiary, Shionogi & Co., Ltd. borrowed a 3,000 hundred million yen bridge loan from Sumitomo Mitsui Banking Corporation. The agreement date and execution date are both 2026-11-10. The final repayment date is 2027-10-29. The loan is planned to be refinanced into medium- to long-term funding before the repayment date. The impact on consolidated results for the fiscal year ending March 2027 is estimated to be minimal.","jir_summary":"### Overview\nShionogi & Co., Ltd. has procured a 3,000 hundred million yen bridge loan from Sumitomo Mitsui Banking Corporation in connection with making IntraBio Inc. a wholly owned subsidiary. The agreement date and execution date are both 2026-11-10, and the final repayment date is 2027-10-29. The funds will be used for acquisition financing, and the company plans to refinance into medium- to long-term funding before the repayment deadline.\n\n### Financial Impact and Outlook\nThe borrowing is expected to have a minimal impact on consolidated results for the fiscal year ending March 2027, and given the nature of the financing, the short-term financial burden is considered limited. Since the repayment and refinancing schedule could affect future capital policy and financial strategy, additional disclosures should be monitored.","jir_financial_highlights":"Borrowed Amount: 3,000 hundred million yen (Unknown)\nAgreement Date: 2026-11-10 (Unknown)\nFinal Repayment Date: 2027-10-29 (Unknown)\nImpact on Results: Minimal (Unknown)","jir_category":"","jir_hashtags":"#Shionogi, #CapitalPolicyFunding","jir_key_figures":"Borrowed Amount: 3,000 hundred million yen\nAgreement Date: 2026-11-10\nFinal Repayment Date: 2027-10-29","jir_meta_title":"Shionogi & Co., Ltd. Announces Bridge Loan for IntraBio Acquisition\uff5cNovember 2026","jir_meta_description":"Shionogi & Co., Ltd. has secured a 3,000 hundred million yen bridge loan as part of financing for the acquisition of IntraBio Inc. Agreement and execution dates, final repayment date, and future refinancing strategy are disclosed. The impact on the fiscal year ending March 2027 is expected to be minimal.","jir_og_title":"Shionogi & Co., Ltd. Announces Bridge Loan for IntraBio Acquisition\uff5cNovember 2026","jir_og_description":"Shionogi & Co., Ltd. has arranged a 3,000 hundred million yen bridge loan to fund the IntraBio acquisition. Agreement, execution, and repayment dates and refinancing plans have been disclosed. The effect on consolidated results is expected to be minimal.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6919,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-147175","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n